How many studies have been conducted on Triggering Receptor Expressed On Myeloid Cells 1?

BiohacksAI has indexed 300 PubMed studies on Triggering Receptor Expressed On Myeloid Cells 1, including 2 randomized controlled trials (RCTs). 51% of studies involve human subjects.

What are the main research areas for Triggering Receptor Expressed On Myeloid Cells 1?

The primary research domains for Triggering Receptor Expressed On Myeloid Cells 1 are 😴 Sleep, 🔬 Inflammation, 🔬 Oncology. This is based on analysis of 300 PubMed studies using the BiohacksAI evidence platform.

Triggering Receptor Expressed On Myeloid Cells 1

An approximately 230 amino acid membrane glycoprotein characterized by an IMMUNOGLOBULIN V-SET DOMAIN in its N-terminal half. It is expressed by MONOCYTES and NEUTROPHILS in response to INFLAMMATION related to bacterial and fungal infections. It triggers the release of pro-inflammatory CHEMOKINES; CYTOKINES, and expression of cell activation markers and is a critical regulator of SEPTIC SHOCK.

300+ PubMed studies analyzed · 2 RCTs · Evidence Score: 54.1

Research Domains

Triggering Receptor Expressed On Myeloid Cells 1 has been studied across 19 research domains including 😴 Sleep, 🔬 Inflammation, 🔬 Oncology, 🛡️ Immunity, 🫁 Respiratory. The primary research focus is 😴 Sleep with 37% of studies addressing this area.

Loading evidence profile...

This evidence profile for Triggering Receptor Expressed On Myeloid Cells 1 is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.